Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.61 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740505 | 0.91 | DRD2 (0.70) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL13042649 | 0.91 | DRD2 (0.70) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL3730334 | 0.88 | DRD2 (0.58) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL8892571 | 0.85 | DRD2 (0.82) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL3806268 | 0.85 | HTR1A (0.62) | DRD2DRD3CHRM3 | |
| SCHEMBL7031018 | 0.83 | DRD2 (0.71) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL6820053 | 0.83 | DRD2 (0.71) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL3733831 | 0.82 | DRD2 (0.59) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL8893091 | 0.81 | DRD2 (0.74) | DRD2DRD4DRD3CHRM2CHRM1 | |
| SCHEMBL3732774 | 0.81 | DRD2 (0.85) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829587-B2 | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | ALLERGAN, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829587-B2 | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | ALLERGAN, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829587-B2 | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | ALLERGAN, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| WO-2009089284-A2 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089284-A2 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ADRA2B, ADRA1B, ADRB2 | DRD2 310/4885DRD4 786/4885DRD3 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.